Breast Cancer Clinical Trials in Boston, Massachusetts

59 studies are recruiting for breast cancer in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

1. E-Mindfulness Approaches for Living After Breast Cancer

   NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants wi…

   Stage

   Phase 3

   Ages

   18 to 50

   Site

   Tufts Medical Center, Boston, Massachusetts

   Locations

   383 in total

   Run by

   NRG Oncology

   See if you can join NCT06748222 on ClinicalTrials.gov

2. Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts

   The over-arching goal of the Contrast-Enhanced Spectral Mammography Imaging Screening Trial (CMIST) is to determine if dual-energy contrast-enhanced spectral mammography (CESM) can detect more cancers with fewer false positives than digital breast tomosynthesis (DBT) in women with dense breasts. Ai…

   Stage

   Not phased

   Ages

   45 to 74

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   13 in total

   Run by

   American College of Radiology

   See if you can join NCT05625659 on ClinicalTrials.gov

3. TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients

   This research is being done to assess whether an exercise intervention with protein intake support vs a health education and support program will make it easier for women age 65 or older who are receiving chemotherapy for breast cancer to receive all of their planned chemotherapy according to sched…

   Stage

   Not phased

   Ages

   65 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   4 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT05535192 on ClinicalTrials.gov

4. Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer

   This research study evaluates the effect of chemotherapy on cognition (thinking) and the brain in people with breast cancer.

   Stage

   Not phased

   Ages

   60 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Massachusetts General Hospital

   See if you can join NCT02290834 on ClinicalTrials.gov

5. Screening For BCRL In Targeted Therapy For Breast Cancer

   This a prospective, longitudinal study designed to track edema and Breast Cancer Related Lymphedema (BCRL) onset in breast cancer patients taking targeted therapy treatments for early and metastatic breast cancer. A Perometer and Sozo devise will be used to measure volume changes

   Stage

   Not phased

   Ages

   18 to 80

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Run by

   Massachusetts General Hospital

   See if you can join NCT05142800 on ClinicalTrials.gov

6. First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

   Study STX-478-101 (LY4064809) is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 (LY4064809) in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherap…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   65 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT05768139 on ClinicalTrials.gov

7. Clonal Hematopoiesis Chemotherapy and Radiation Effects Study

   The goal of the Clonal Hematopoiesis Chemotherapy and Radiation Effects (CH CARE) Study is to understand how the presence or absence of clonal hematopoiesis (CH) influences outcomes in people receiving chemotherapy and radiation for solid cancers. The study will collect biospecimens and clinical in…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT07675967 on ClinicalTrials.gov

8. A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

   A Study of Emi-Le in Participants with Solid Tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Beth Israel Deaconess Medical Center, Boston, Massachusetts

   Locations

   26 in total

   Run by

   Day One Biopharmaceuticals, Inc.

   See if you can join NCT05377996 on ClinicalTrials.gov

9. Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

   This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor [HR]-negative and HR-positive) unresectable and/or metastatic breast cancer.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   88 in total

   Run by

   Daiichi Sankyo

   See if you can join NCT05950945 on ClinicalTrials.gov

10. ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer

    The goal of this study is to evaluate the safety and efficacy of elacestrant in combination with trastuzumab deruxtecan (T-DXd) in participants with hormone receptor-positive (HR+), HER2-low or HER2-ultralow, metastatic breast cancer that is resistant to prior CDK4/6 inhibitor and endocrine therapy…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Run by

    Kristina A. Fanucci

    See if you can join NCT07198724 on ClinicalTrials.gov

11. Oncoplastic Surgery Outcomes Database

    This is a retrospective and prospective chart review of surgical outcomes and collecting patient satisfaction outcomes using validated surveys for oncoplastic breast surgery and Goldilocks mastectomy.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Tufts Medical Center, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Tufts Medical Center

    See if you can join NCT07597837 on ClinicalTrials.gov

12. Video Education With Result Dependent dIsclosure

    The overall study objective of this trial study is to identify and evaluate strategies to improve the accessibility of the video education with result dependent disclosure (VERDI) model, increasingly utilized as a pre-genetic testing (pretest) education alternative in clinical practice, to better s…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT05225428 on ClinicalTrials.gov

13. Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

    Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute ( Site 0050), Boston, Massachusetts

    Locations

    18 in total

    Run by

    Merck Sharp & Dohme LLC

    See if you can join NCT06686394 on ClinicalTrials.gov

14. Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

    This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib and palbociclib plus endocrine therapy for the treatment of patients with locally advanced or metastatic HR+/HER2- advanced breast cancer.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Massachusetts General Hospital Cancer Center, Boston, Massachusetts

    Locations

    203 in total

    Run by

    Celcuity Inc

    See if you can join NCT06757634 on ClinicalTrials.gov

15. IKS014 in Advanced Solid Tumors That Express HER2

    This study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS014, a HER2 targeting antibody-drug conjugate, in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Locations

    13 in total

    Run by

    Iksuda Therapeutics Ltd.

    See if you can join NCT05872295 on ClinicalTrials.gov

16. Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial

    This research is to evaluate the effectiveness of Talazoparib as a potential treatment for metastatic breast cancer with a BRCA 1 or BRCA 2 mutation.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Massachusetts General Hospital Cancer Center, Boston, Massachusetts

    Locations

    7 in total

    Run by

    Massachusetts General Hospital

    See if you can join NCT03990896 on ClinicalTrials.gov

17. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

    This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Massachusetts General Hospital, Boston, Massachusetts

    Locations

    6 in total

    Run by

    ModeX Therapeutics, An OPKO Health Company

    See if you can join NCT06239194 on ClinicalTrials.gov

18. Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

    The purpose of this study is to determine if a combination of two drugs sacituzumab govitecan and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: * Sacit…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    7 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04434040 on ClinicalTrials.gov

19. VS-6766+Abema+Fulv in Met HR+/HER- BC

    This research is being done to evaluate the safety and effectiveness of a drug currently known as VS-6766 in combination with the drugs abemaciclib and fulvestrant in HR+/HER2-negative breast cancer. The names of the study drugs involved in this study are: * VS-6766 * Abemaciclib * Fulvestrant

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Brigham and Women's Hospital, Boston, Massachusetts

    Locations

    3 in total

    Run by

    Adrienne G. Waks

    See if you can join NCT05608252 on ClinicalTrials.gov

20. Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

    This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: * …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Dana Farber Cancer Institute, Boston, Massachusetts

    Locations

    15 in total

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT04468061 on ClinicalTrials.gov

21. Exercise in Metastatic Breast Cancer: EMBody

    The purpose of this study is to study exercise in a novel population with indolent MBC (no progression on current therapy in prior 12 months and not receiving cytotoxic chemotherapy). The study team hypothesizes that delivering virtual, supervised, progressive intensity aerobic and resistance train…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    6 in total

    Run by

    Indiana University

    See if you can join NCT05468034 on ClinicalTrials.gov

22. Individualizing Approaches to Surveillance Mammography in Older Breast Cancer Survivors - The I-MAMMO Study

    This study evaluates the effectiveness of a Shared Decision-Making (SDM) toolkit designed to support older breast cancer survivors aged 80 and above in making informed decisions about continuing surveillance mammography.

    Stage

    Phase 2

    Ages

    80 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT07123649 on ClinicalTrials.gov

23. Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer

    This clinical trial will assess the safety and early efficacy of Hydroxychloroquine or Avelumab, with or without Palbociclib, in early-stage ER+ breast cancer patients who are found to harbor disseminated tumor cells (DTCs) in the bone marrow after definitive surgery and standard adjuvant therapy.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    7 in total

    Run by

    Abramson Cancer Center at Penn Medicine

    See if you can join NCT04841148 on ClinicalTrials.gov

24. SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers

    Investigators aim to conduct a type 1 hybrid effectiveness-implementation surgeon-level cluster randomized clinical trial (RCT) of a multi-level intervention, a shared decision making training for surgeons plus patient decision aid vs. usual care (UC), at 7 large health systems across the U.S. to l…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Beth Israel Deaconess Medical Center, Boston, Massachusetts

    Locations

    11 in total

    Run by

    Beth Israel Deaconess Medical Center

    See if you can join NCT06896474 on ClinicalTrials.gov

25. Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

    Incyclix Bio (Incyclix) is developing INX-315 as an oral, small molecule inhibitor of cyclin dependent kinase 2 (CDK2) for the treatment of human cancers. This first-in-human study is designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary antitumor activity of INX-315 …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Locations

    18 in total

    Run by

    Incyclix Bio

    See if you can join NCT05735080 on ClinicalTrials.gov